Renal Cell Carcinoma

Quick Answer

Renal cell carcinoma (RCC) is highly vascular and, for the clear-cell subtype, biologically defined by VHL loss → HIF activation. Nuclear medicine has a limited role for the primary tumor (FDG is variably avid and urinary excretion obscures the kidney) but is useful for metastatic staging/restaging and prognosis. Two molecular avenues are reshaping RCC imaging: PSMA-PET (PSMA is expressed in tumor neovasculature) for metastatic ccRCC, and the CAIX-targeted antibody girentuximab — ⁸⁹Zr-girentuximab for characterizing indeterminate renal masses (ZIRCON), with ¹⁷⁷Lu-girentuximab as an investigational theranostic.

Definition

RCC is a malignancy arising from the renal tubular epithelium. The dominant subtype is clear-cell (ccRCC), followed by papillary (types 1 and 2) and chromophobe; rarer aggressive subtypes exist (collecting-duct, medullary, translocation).

Synonyms

Renal cell carcinoma (RCC); clear-cell RCC (ccRCC); hypernephroma (obsolete); "Grawitz tumor" (historical).

Epidemiology

RCC accounts for a small percentage of adult cancers, with a male predominance and peak incidence in the sixth–seventh decades. Incidence has risen, driven largely by incidental detection on cross-sectional imaging. Most cases are sporadic; a minority are hereditary.

Etiology & Risk Factors

• Smoking, obesity, hypertension, and acquired cystic disease of dialysis.
• Hereditary syndromes: VHL (ccRCC), hereditary papillary RCC (MET), Birt–Hogg–Dubé (chromophobe/oncocytoma), and HLRCC (FH, aggressive type-2 papillary).

Pathophysiology

Clear-cell RCC is driven by biallelic VHL inactivation → failure to degrade HIF → constitutive transcription of VEGF and carbonic anhydrase IX (CAIX). This explains RCC's intense angiogenesis (rationale for antiangiogenic therapy), CAIX overexpression (the girentuximab target), and PSMA expression in tumor neovascular endothelium. RCC metastasizes to lung, bone (often lytic), liver, and brain — and characteristically to unusual/late sites (pancreas, thyroid, soft tissue).

Genetics & Molecular Biology

• ccRCC: VHL (chromosome 3p), plus PBRM1, BAP1, SETD2 (prognostic).
• Papillary type 1: MET; type 2 / HLRCC: FH.
• Chromophobe: distinct genomics (Birt–Hogg–Dubé/FLCN).
• CAIX (HIF-driven) is a near-universal ccRCC surface antigen — the basis for girentuximab imaging/therapy.

Histopathology

• Clear cell: lipid/glycogen-rich clear cytoplasm, delicate vasculature.
• Papillary: papillae with foamy macrophages (type 1) or higher-grade eosinophilic cells (type 2).
• Chromophobe: perinuclear halos, raisinoid nuclei.
• Graded by the WHO/ISUP nucleolar grade; sarcomatoid change is adverse.

Clinical Presentation

Most RCC is now asymptomatic and incidentally detected. The classic triad (flank pain, hematuria, palpable mass) is late and uncommon. Paraneoplastic phenomena are characteristic: polycythemia (EPO), hypercalcemia (PTHrP), and Stauffer syndrome (non-metastatic hepatic dysfunction).

Laboratory Findings

No specific serum marker. LDH, calcium, hemoglobin/neutrophils/platelets, and performance status feed the IMDC prognostic model in metastatic disease.

Imaging Findings by Modality

• CT / MRI (primary tools): characterize the renal mass (enhancement, fat, complexity), stage, and detect metastases.
• Ultrasound: cystic-vs-solid and screening in at-risk patients.
• FDG-PET: limited for the primary (variable avidity; urinary excretion obscures the kidney) but useful for metastatic staging/restaging and prognosis (avid disease behaves worse).
• PSMA-PET: emerging for metastatic ccRCC (neovascular PSMA), often more sensitive than FDG/CT for small metastases.
• ⁸⁹Zr-girentuximab PET (CAIX): characterizes indeterminate renal masses as ccRCC (ZIRCON trial: high sensitivity/specificity).
• Bone scan: insensitive (RCC bone metastases are often lytic).

Radiopharmaceutical Uptake Mechanisms

FDG reflects glucose metabolism (variable in RCC; low in some well-differentiated tumors). PSMA localizes to tumor neovascular endothelium (not the tumor cells themselves). CAIX is a HIF-driven transmembrane enzyme highly and selectively expressed on ccRCC cell membranes — the girentuximab antibody target for both imaging (⁸⁹Zr) and therapy (¹⁷⁷Lu).

Typical PET Tracers

Typical SPECT Tracers

• Bone scan (limited — lytic metastases).
• (Historical) ¹²³I/¹¹¹In-girentuximab SPECT — superseded by ⁸⁹Zr-PET.

Therapy Indications

• Localized: partial or radical nephrectomy, thermal ablation, or active surveillance of small renal masses.
• Metastatic: antiangiogenic TKIs (sunitinib, pazopanib, cabozantinib, lenvatinib), mTOR inhibitors (everolimus, temsirolimus), and immune-checkpoint combinations (ipilimumab+nivolumab; pembrolizumab-based doublets) — now first-line in many settings.
• Investigational: ¹⁷⁷Lu-girentuximab (CAIX radioligand therapy).

Theranostics

RCC's emerging theranostic is CAIX-directed: ⁸⁹Zr-girentuximab confirms ccRCC (imaging/characterization — ZIRCON), and ¹⁷⁷Lu-girentuximab delivers targeted therapy (investigational) — an antibody-based image-and-treat pair analogous in logic to PSMA/SSTR theranostics. PSMA-PET additionally exploits ccRCC neovascular PSMA for metastatic detection.

Differential Diagnosis

• Oncocytoma and fat-poor angiomyolipoma (benign; oncocytoma is typically CAIX/girentuximab-negative).
• AML with macroscopic fat (CT diagnostic), complex cysts (Bosniak), lymphoma/metastasis to the kidney.
• Physiologic urinary activity mimicking or obscuring the primary on FDG.

Reporting Checklist

• Characterize the renal mass (enhancement, fat, complexity) and stage; for FDG, note the urinary-excretion limitation for the primary.
• Emphasize metastatic detection/restaging and prognostic avidity.
• State PSMA or CAIX/girentuximab findings in the appropriate (often trial/emerging) context.
• Recognize RCC's unusual metastatic sites (pancreas, thyroid, soft tissue).

Prognosis

Localized RCC is often curable by surgery/ablation. Metastatic prognosis follows the IMDC risk model (performance status, time to systemic therapy, hemoglobin, calcium, neutrophils, platelets), subtype, grade, and sarcomatoid features. Immunotherapy combinations have improved advanced-disease outcomes.

Board Pearls

Nuclear medicine has a limited role for the RCC primary (FDG is variably avid and urinary excretion obscures the kidney) but is useful for metastatic staging/restaging and prognosis. PSMA-PET (neovascular PSMA) is emerging for metastatic ccRCC, and ⁸⁹Zr-girentuximab (CAIX) characterizes indeterminate renal masses as ccRCC (ZIRCON).

RCC bone metastases are often lytic — the bone scan is insensitive; and RCC seeds unusual/late sites (pancreas, thyroid, soft tissue), so review whole-body studies deliberately.

The biology ties it together: VHL loss → HIF drives VEGF (antiangiogenic therapy), CAIX (girentuximab image-and-treat: ⁸⁹Zr → ¹⁷⁷Lu, investigational), and neovascular PSMA (metastatic detection). Oncocytoma is typically girentuximab/CAIX-negative, a useful benign discriminator.

Related Pages

• Tracers: PSMA PET agents, FDG.
• Related disease: Prostate cancer (PSMA context), von Hippel–Lindau overlap (see MEN/hereditary syndromes).
• Pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• A VHL → HIF → VEGF/CAIX/PSMA pathway diagram tying biology to tracers/therapy.
• A CAIX theranostic loop (⁸⁹Zr-girentuximab image → ¹⁷⁷Lu-girentuximab treat).
• An RCC metastatic-site whole-body plate (including unusual sites).

Common Pitfalls

• Low-grade / well-differentiated clear-cell RCC is frequently FDG-non-avid — a negative FDG-PET does not exclude viable tumor or metastasis, so avidity is prognostic but insensitive for indolent disease.
• Intense urinary excretion can obscure a post-nephrectomy renal-bed recurrence or mimic a hilar/perinephric lesion — use hydration, a diuretic, and delayed imaging.
• Papillary and chromophobe RCC are often CAIX-negative, so a negative ⁸⁹Zr-girentuximab study does not exclude non-clear-cell RCC; the agent is validated for characterizing indeterminate solid masses as ccRCC, not for excluding cancer.
• RCC brain metastases are poorly FDG-avid against high cortical background — do not rely on FDG-PET for intracranial disease; use dedicated brain MRI.

Self-Check (Board-Style)